Evidence map›Paper›PMID 41411524›Full record

ArticleBlood advances2026

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Vanja Zeremski, Enver Aydilek, Akhil Behringer, Franziska Brunner, Tobias R Haage, Mathias Haenel, Igor Kos, William Krueger, Georg Lenz, Vadim Lesan and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Vanja ZeremskiDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Enver AydilekDepartment for Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany.ORCID 0000-0003-1418-2725
Akhil BehringerMedical Department A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
Franziska BrunnerDepartment of Internal Medicine IV, Hematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Tobias R HaageDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Mathias HaenelDepartment of Internal Medicine III, Hematology, Oncology and Cell Therapy, Klinikum Chemnitz, Chemnitz, Germany.
Igor KosInternal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.
William KruegerDepartment of Internal Medicine C, University Medical Center Greifswald, Greifswald, Germany.
Georg LenzMedical Department A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
Vadim LesanInternal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.
Jessica SchneiderDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-7850-4987
Christian Schultze-FloreyDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-3307-2639
Evgenii ShumilovMedical Department A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.ORCID 0000-0003-0178-1729
Thomas WeberDepartment of Internal Medicine IV, Hematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.ORCID 0000-0002-8724-9348
Gerald WulfDepartment for Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany.
Vladan VucinicDepartment of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.ORCID 0000-0002-8398-285X
Dimitrios MougiakakosDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.ORCID 0000-0002-2817-6660

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41411524
PMCPMC13052050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.